MAP2K7 and RASopathy: The MEK inhibitor selumetinib is the first FDA-approved treatment for patients with a RASopathy, in particular, pediatric patients with NF1 who have symptomatic, inoperable plexiform neurofibromas (Gross et al., 2020b).